Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: GlobeNewswire
2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025, at 4:30 p.m. ET CELEBRATION, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and nine months ended September 30, 2025. "Zevra is well-positioned for continued growth, driven by the strong performance of MIPLYFFA and the meaningful impact we are delivering to patients with Niemann-Pick disease type C," said Neil F. McFarlane, Zevra's President and Chief Executive Officer. "We have generated strong revenue and a solid operating runway that enables us to execute on our strategic priorities and invest in building Zevra into a leading rare disease company." Commercial Highlights MIPLYFFA: Eight prescription
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewswire
- Zevra Therapeutics, Inc. Announces CFO Transition [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics announces CFO transition [Seeking Alpha]Seeking Alpha
- Zevra Therapeutics, Inc. Announces CFO TransitionGlobeNewswire
- Analysts Have Lowered Expectations For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Latest Results [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 12/2/25 - Form 8-K
- 11/20/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- ZVRA's page on the SEC website